Financials
- Financial year
- 2025
- Total assets
- €61,934
- Profit
- €33,287
- Solvency
- 58.6%
ITIPHARMA GHYSELEN
ActiveSummary
ITIPHARMA GHYSELEN has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €36,287 and a net result of €33,287. Its solvency ranks better than 71% of 22,027 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€61,934total assets 2025
- Equity
- €36,287
- Profit
- €33,287
Turnover not published (micro format)
Why 92raises riskFounded in 2025Size: total assets €61,934lowers riskLiquidity: current ratio 2.36, cash €47,464Equity €36,287 (58.6% of total assets)Show the evidence
Checked score
Score 2025
92
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 84% of its sector peers (NACE 47, micro)
Financial strength
Strong
Solvency
84
equity 58.6% of total assets
Liquidity
80
short-term debt 41.4% · cash 76.6%
Profitability
100
return on assets 53.7%
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Credit of up to €3,000 on 30-day terms is acceptable
Liquidity ample (current ratio 2.36, above the usual 1.5; short-term debt: 41.4% and cash: 76.6% of total assets), and 41.4% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 72% on solvency, 84% on liquidity and 96% on profitability.
The bankruptcy probability was computed on 13-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-07-2026, 21 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
21 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
- Annual accounts filedfinancial year 2025 · micro…
- IncorporationAppointment: GHYSELEN Geoffrey Henri Germain…
Key points
By topic
Board & ownership
- Board
- 1 member
- GHYSELEN Geoffrey Henri GermainDirector
Timeline
- Events
- 2
- Since
- 2025
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 07-10-2025
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 32
- Who signs
- Each director alone
- Purpose
- “L’organisation, l’exploitation, la gestion et l’administration d’officines…” (deed in French)
- Statutory auditor
- No statutory auditor
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Roughly what is this company worth?Value indication
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.